



- Bilcare was selected to represent India to the working group of IMPACT-WHO (International Medical Products Anti-Counterfeiting Taskforce of World Health Organization) engaged in steering the anti-counterfeit initiative for the global pharmaceutical sector.
- Bilcare Global Clinical Supplies formed the Advisory Board with the induction of Dr. John LaMatinna, former President (R&D), Pfizer and Dr. Arthur Carty, Executive Director, Waterloo Institute of Nanotechnology.
- Bilcare Global Clinical Supplies, a leading single-source provider of clinical trial services, announced the completion of a major expansion of capacity at its facility in Phoenixville, PA, US.
- Controller of Patents upheld Bilcare’s Patent on Patina.

- DMF regd. with USFDA
- EEC / USP
- Member, IQA, London
- OPPI Award Winner
- Pioneer Status from Govt. of Singapore
- ISO 9001:2000 & 14001:2004 Company

Bilcare, a unique organization with a strong research foundation and an unending quest for global leadership. An organization, integrated with global Pharmaceuticals having best in class manufacturing and research facilities spread worldwide. An organization made up of motivated people who go that extra mile to spread excellence and joy.

INDIA : USA : SINGAPORE : GERMANY : BRAZIL : CHINA : UK

**Bilcare Limited** - Regd. Office : 1028, Shirol, Pune 410 505.

**Audited Financial Results for the year ended 31st March, 2008**

(Rs. in Crores)

Sr. No.	Particulars	Year ended 31/03/2008 (Audited)	Year ended 31/03/2007 (Audited)	Consolidated Period ended 31/03/2008 (Audited)	Consolidated Year ended 31/03/2007 (Audited)
1.	Net Sales/Income from Operations	406.35	322.98	650.68	407.85
2.	Other Income	15.77	18.46	19.24	17.87
3.	Total Income (1+2)	422.12	341.44	669.92	425.72
4.	Expenditure				
a.	(Increase)/decrease in stock in trade and work in progress	(8.06)	(1.95)	(6.41)	(5.15)
b.	Consumption of Raw Materials	247.57	198.91	361.50	248.39
c.	Employees Cost	15.64	12.00	60.55	22.39
d.	Depreciation	15.71	10.72	24.16	15.44
e.	Other Expenditure	38.29	23.98	91.57	43.11
f.	Total	309.15	243.66	531.37	324.18
5.	Interest	11.44	7.97	14.27	9.11
6.	Profit before Tax (3) - (4+5)	101.53	89.81	124.28	92.43
7.	Tax Expense	39.84	31.25	42.73	32.51
8.	Net Profit after Tax (6-7)	61.69	58.56	81.55	59.92
9.	Paid-up Equity Share Capital (face value Rs.10/- each)	16.45	14.20	16.45	14.20
10.	Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year	346.79	184.33	372.39	189.70
11.	Earnings Per Share (EPS - Rs.)				
a.	Basic	37.49	41.24	-	-
b.	Diluted	32.14	35.29	-	-
12.	Public Shareholding				
-	Number of shares	9,176,791	7,619,526	9,176,791	7,619,526
-	Percentage of shareholding	55.78%	53.66%	55.78%	53.66%

Notes:

1. A dividend of 40% on Equity shares has been recommended at the Board Meeting subject to the approval of the Members.
2. The Company's main business segment is pharma packaging research solutions.
3. The Company had received 1 investor complaint during the period, which was redressed and there were no investor complaints pending for redressal at the commencement and at the end of the period.
4. The Consolidated results include operation of its subsidiaries namely i) Bilcare Singapore Pte Ltd., Singapore ii) Bilcare GmbH, Germany iii) Bilcare Inc., USA iv) Bilcare Farmaceutica Embalagem E Pesquisas Ltda., Brazil v) Bilcare (UK) Ltd., UK vi) Bilcare GCS (Europe) Ltd., UK, (formerly DHP Ltd.) vii) Singular ID Pte Ltd., Singapore viii) Singular ID Italia Srl, Italy. The year end of all the subsidiary companies has been brought to a uniform closing to 31st March. As a result for the period ended 31st March, 2008 the financials of the subsidiaries are for 15 months and hence not comparable with the previous years figures.
5. The previous years figures have been regrouped / readjusted wherever necessary.
6. The above Audited Financial Results were taken on record by the Board of Directors of the Company at its meeting held on 30th June, 2008.

**For Bilcare Limited**

**Mohan H. Bhandari**  
Managing Director

Pune : 30th June, 2008